/r/biotech_stocks

Photograph via snooOG

Biotechnology & Pharmaceuticals Stock News & Analysis.

Let's go get it boyz!! No clickbait titles permitted.

Post titles should list the company ticker symbol in BRACKETS and then the title of the post should reproduce the title page as faithfully as possible. Editorializing is for the comments section.

/r/biotech_stocks

14,842 Subscribers

1

Understanding the Benefits of Mainz Biomed's NASDAQ: MYNZ Reverse Stock Split

Mainz Biomed MYNZ recently announced a 1-for-40 reverse stock split of its common shares, set to take effect on December 3. Here’s why this move could benefit investors:

  1. Maintains Nasdaq Compliance The reverse split ensures MYNZ remains listed on the Nasdaq by meeting the minimum bid price requirement of $1. This secures the company’s visibility on a major exchange and protects investor confidence.
  2. Enhanced Market Perception With a higher post-split share price, MYNZ positions itself as a more stable investment, potentially attracting institutional investors and broadening its shareholder base.
  3. Improved Liquidity A consolidated share structure often results in more efficient trading, benefiting both existing and potential investors.
  4. Focus on Long-Term Growth This strategic move reflects MYNZ’s commitment to strengthening its market position while continuing to innovate in the molecular genetic diagnostics space.

For investors, this reverse stock split is not just about compliance ’s a step toward positioning MYNZ for future growth and success.

https://preview.redd.it/pmppinvtih4e1.png?width=371&format=png&auto=webp&s=73d3eeb5e359567a99b20e0b0f9fb4d759892598

0 Comments
2024/12/02
19:14 UTC

2

Y-mAbs Therapeutics: From Promising Cancer Treatment to a 70% Stock Crash

In 2020, Y-mAbs announced Omburtamab as a groundbreaking cancer therapy. By 2022, the FDA denied approval due to weak data, and the stock dropped over 70%.

Check out the full Y-mabs story and how YMAB investors can recover their losses now:

https://www.benzinga.com/general/biotech/24/11/42135598/y-mabs-omburtamab-failure-the-critical-turning-point-and-19-65m-shareholder-settlement 

0 Comments
2024/12/02
18:45 UTC

0

Mainz Biomed NV (NASDAQ: MYNZ): A Promising Prospect in Molecular Diagnostics

Mainz Biomed NV (NASDAQ: MYNZ) has received a "Hold" rating from analysts, reflecting a measured confidence in its position as a leader in molecular diagnostics. The company is driving innovation in colorectal cancer detection through advanced genetic testing and strategic collaborations, aiming to revolutionize healthcare outcomes.

This rating underscores a cautious yet optimistic outlook as Mainz Biomed continues to make headway in precision medicine. Both investors and healthcare stakeholders should watch closely as the company navigates the ever-evolving diagnostic technology landscape.

Source

3 Comments
2024/12/02
15:25 UTC

1

George Starke Teams Up with NASDAQ: MYNZ Mainz Biomed and Thermo Fisher to Tackle Colorectal Cancer

0 Comments
2024/12/02
12:45 UTC

2

Exciting Updates from Mainz Biomed (NASDAQ: MYNZ): Major Developments Ahead

Mainz Biomed is making big moves in the biotech world with three significant updates that you need to know:

Reverse Stock Split on Monday

Mainz Biomed will undergo a reverse stock split on Monday, a strategic step to enhance share value and better position the company for growth. This move aims to attract institutional investors and strengthen the company’s market position.

Partnership with Thermo Fisher Scientific

In a groundbreaking collaboration, Mainz Biomed has partnered with Thermo Fisher Scientific, a global leader in life sciences. This partnership will accelerate the development and distribution of Mainz's innovative diagnostics solutions, reinforcing their leadership in early cancer detection and beyond.

More Big News Coming up ahead

Mark your calendars. Mainz Biomed is set to announce major news on Tuesday. With its track record of innovation and now bolstered by its partnership with Thermo Fisher Scientific, this announcement could signal a transformative moment for the company and the biotech sector. Why It MattersMainz Biomed’s commitment to revolutionizing early cancer diagnostics, combined with the support of industry giants like Thermo Fisher Scientific, positions the company for extraordinary growth and impact.

What are your thoughts on these exciting developments for Mainz Biomed?

0 Comments
2024/11/30
23:17 UTC

1

$nkgn

M

0 Comments
2024/11/30
06:40 UTC

1

Deadline For Getting Payment On Bioventus's $15.25M Investor Settlement is Next Week

Hi there, I guess there are some Bioventus investors here. And, that we are really happy about it since they have reached a remarkable 52-week high, and a Q2 with a 14% increase in organic revenue growth. That’s great news and a nice rebound after the financial issues they had last year (hopefully).

For those who missed it, back in 2023, Bioventus reported a decline in sales for 2022. They said it was over unexpected refund claims from customers and lower-than-expected average selling prices. But when this news came out, $BVS dropped and investors filed a claim against them.

The good news is that Bioventus decided to settle $15.25M with investors to resolve this situation. Deadline is next week. So if you were an investor back then, you can check it out and file for the payment.

Anyways, what are your expectations for the coming year? And has anyone here been affected by these financial issues back then? How much were your losses if so? 

0 Comments
2024/11/29
19:27 UTC

2

ELDN T1D cure

Eledon pharmaceuticals, inc. deals with islet transplantation immunosuppression, looks like they’ve effectively cured 2 patients with 1 more patient that is on track to be cured of type 1 diabetes. They’ve completed enrollment of 120 subjects for phase 2.

This seems really exciting. Stock price has rallied quite a bit recently, and I took a starter. Market cap ~$278m

2 Comments
2024/11/29
18:55 UTC

2

Mainz Biomed Initiates Transformative Stock Split and Partners with Thermo Fisher Scientific for Cancer Screening Advancements

0 Comments
2024/11/29
17:00 UTC

2

Quick Summary of Mainz Biomed's Corporate Strategy and Collaborative Effort

Mainz Biomed NV is gearing up for a 1-for-40 reverse stock split on December 3, 2024, which will consolidate every 40 shares worth $0.25 each into one share valued at $10. This move is designed to enhance the share's market appeal and ensure compliance with Nasdaq standards. Additionally, Mainz Biomed has entered into a strategic partnership with Thermo Fisher Scientific to develop and expand the reach of ColoAlert®, their test for colorectal cancer. This partnership aims to leverage Thermo Fisher’s extensive technology resources, potentially accelerating product development and increasing market penetration, thereby boosting shareholder value.

source: https://mainzbiomed.com/news/

0 Comments
2024/11/29
16:32 UTC

1

RenovoRx's TAMP Therapy: A Revolutionary Approach to Combating Pancreatic Cancer

https://preview.redd.it/us8fwq770v3e1.png?width=400&format=png&auto=webp&s=ca626a4937581133f04fd3598890bd3b78a59e31

Renovo (RenovoRx Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform. Oncologist is an international peer-reviewed Journal for practicing oncologists and hematologists.

https://preview.redd.it/5omswa580v3e1.png?width=266&format=png&auto=webp&s=5ef4b9955e0ecfec5d4ef62bbeee214a98e5898b

Behind all this biotech is a very good therapy with potential to lower deadly numbers of Pancreatic Cancer. Targeting Pancreatic Cancer, which has a 5-year survival rate of 13% (and that's stage 1-4). That is 18 percent of patients a year. Moreover, 13% will not survive past five tears. As we all know, Pancreatic cancer is a nasty, nasty disease. (Previous article)

Average survival rate is 3.5 years. If the disease is note dealt with, Pancreatic cancer can go from stage one to stage four in a year. Survival is basically nil. The work of RenovoRx is obvious and a possible scourge of this killer.

https://preview.redd.it/hvt7glye0v3e1.jpg?width=1200&format=pjpg&auto=webp&s=1569b452fb8b5dea19f5dcf8cc04cbf49c10f837

Recently the Company increased production of its FD cleared RevenoCath due to medical need for targeted therapeutic/drug delivery from Oncologists. Delivery is based on the Company’s Local Drug Delivery Program (LAPD). Progress continues with the Company’s previous announced Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The chart shows active shares even in the reality of low volume. Volatility on low volume be you friend. Sometimes.

https://preview.redd.it/zxbd345m0v3e1.png?width=1118&format=png&auto=webp&s=efa7d4f6f17a61c7e8b470b121ecb54b9bf0f1c5

Leesa Gentry, Chief Clinical Officer of RenovoRx, commented, “As we continue to make steady progress with our pivotal Phase III trial in LAPC, we have received feedback from oncology and interventional radiology physicians and key opinion leaders expressing the desire to purchase RenovoCath as a standalone device to be used in clinical practice. RenovoCath has been used in over 500 procedures by interventionalists over the past several years. We have published data from completed early-stage clinical trials that highlight the potential benefits to patients receiving targeted therapy with RenovoCath, including less toxicity and better outcomes, over the current standard of care.”

Cancer Research UK Stats

So as one can see, the odds are not in the least in the patients’ corner. Current therapies for this horrible and usually fatal disease; “Resectable (surgical removeable) pancreatic tumours can be completely removed with surgery. Stage 1 or 2 tumours are often resectable. They are treated with surgery to remove part, or all, of the pancreas. Chemotherapy may be given after surgery (called adjuvant chemotherapy). If cancer cells are found in the tissue removed along with the tumour during surgery (called positive surgical margins), radiation therapy or chemoradiation may be given. (Canadian Cancer Society)

RNXT’s therapy is quite ingenious and seems to have caught the attention of the FDA and its ilk for perhaps fast tract approval. Obviously, doctors and patients are keen to utilize the therapy.

RenovoRx The therapeutic approach of TAMP is specifically designed for the localized and targeted delivery of chemotherapy via the peripheral vascular system. Our patented delivery system is inserted into an artery that runs adjacent to the tumor via an approximately 4 mm incision made in the patient’s leg. RenovoCath’s double balloon design enables the physician to isolate sections of the blood vessel through the adjustment of the distance between the balloons, thereby excluding any side branches in order to create the pressure head needed to push chemotherapy across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.

Liver cancer tumors are highly vascularized and typically have large tumor feeders or blood vessels connected to the tumor, making them better candidates for systemic chemotherapy because medicine is able to gain direct access to the tumor. In contrast, pancreatic cancer tumors lack visible tumor feeder blood vessels, which means the chemotherapy circulates through the body, without a signi­ficant amount of medicine reaching the tumor.

To sum up, RNXT manages to ‘bathe’ the tumor in chemotherapy as opposed to the kind of hit and miss of chemo alone. The recurrence of tumours is also quite likely and due the fact of a lack of blood vessels in a pancreatic tumour, the RNXT’s approach seems to have merit and promise.

This therapy and RNXT other research will eventually be applicable to many cancers and are in various stages of regulatory, Phase studies and development, evidencing what could be a page turner in the cancer scourge, particularly the almost always lethal pancreatic.

Likely a place in your holdings should be allocated.

Here’s RNXT’s roundup of therapies, studies, etc.

10xAlerts has been received compensation from the issuer for News Dissemination, Content and Social Media Services.

1 Comment
2024/11/29
15:33 UTC

4

Looking for Starter Material

Hi everyone, I've decided to take up learning medicine/biotech investing. I wanted to ask what recommendations people have for books, videos, courses, or other materials that you think would be good primers?

Also if anyone has checklists or wants to share their due diligence process, that would also be useful.

I'd also love to know what investors to study. I've read For Blood and Money and learned about Rothbaum, Duggan, and Edelman. Three legends. Thank you!

12 Comments
2024/11/29
05:33 UTC

4

$BOT (ASX:BOT) Botanix is the most mispriced pre-commercialisation biotech in Australia (ANALYSIS)

Description

**Overview**
Botanix Pharmaceuticals (ASX:BOT) is a clinical dermatology company based in the US, but listed on the Australian Securities Exchange. Recently BOT has received FDA approval for its premier product Sofdra, which is a targeted treatment for primary axillary hyperhidrosis (PAH). 

Hyperhidrosis is a condition which sees increased sweating, beyond a regular requirement of the body. It is the third largest dermatology condition, behind acne and dermatitis. PAH is characterised by excessive under-arm sweating, and is the target of Sofdra. 

The sections below which will be discussed include:
- Sofdra and PAH
- market opportunity
- other pipeline
- management
- strategy
- financials
- events
- other notes
- value
- key risks
- thesis 

**Sofdra and PAH**
Sofdra - sofpironium bromide gel, 12.45% - is a once-daily topical anticholinergic therapy (basically blocks nervous responses, like sweating) which can be used for adults and children 9 years of age and older. 
It is an underarm cream which you apply, similar to how you would apply deodorant. 

Received FDA approval mid-2024, though the actual product received FDA approval in 2023 with the issue of 'complete' approval being because of poor labelling.

PAH affects 1 in 40 people globally. Despite its prevalence, poor treatments, stigma and unawareness lead to, almost 80% of sufferers are left untreated. Treatment 

The PAH/HH community has had limited options for treatment, with options such as botox injections, heat energy devices or even cutting nerves. Some clinicians even recommend just deodorant as they see no value add from the current market options. 
PAH/HH is ranked as one of the hardest to manage conditions by dermatologists, with current solutions. 
Sofdra is considered as an effective, easy to use, well-tolerated and safe alternative, which ticks all the boxes for users. 85% of dermatologists would prescribe Sofdra gel, and see it as a significant breakthrough for PAH sufferers. 

Initially, Sofdra was a product from Brickell Biotech though was acquired by BOT, after Dr Patricia Walker (CMA, see Management segment) left Brickell to join BOT. First thoughts are that Dr Walker must have had massive conviction of Sofdra prior to joining BOT if her first move with BOT was to acquire it off her prior employer. This was realised with Sofdra receiving complete FDA approval in 2024.

**Market Opportunity**
As mentioned above, 1 in 40 people suffer from PAH globally. 
Currently, BOT is looking to commercialise Sofdra in the US (see other notes for details on other markets). 
3.7m patients seek treatment for PAH in the US (high priority);
10.0m are diagnosed (priority), and;
16.1m suffer from any form of HH.

**Other Pipeline**
This is only a short overview, as these products are immaterial to the current value of BOT. 

BOT is currently in the R&D phases of several early-stage dermatology products, though these are still deep in the pipeline and are not the main priority. These primarily focus on acne treatments, though they have not seen any significant progress. 

Product - Indication - Status
BTX1503 - moderate to severe acne - pending Phase 3 study
BTX1702 - Rosacea - Positive Phase 1b/2 results
BTX1204A - Atopic dermatitis - Canine proof-of-concept study complete
BTX1801 - Antimicrobial - Phase 2a study (successfully completed), Phase 2b (pending)

**Management**
BOT management team is extremely experienced, having developed, approved and commercialised +30 unique products. A key example is Anchor Pharmaceuticals which was acquired by Pfizer for $5.2bn USD prior to FDA approval. 

Key figures:
Vince Ippolito - Executive Chairman
COO of Anchor and Medicis, ex-President of Dermavant, 17y at Novartis

Howie McKibbon - CEO
ex-SVP Commercial of Dermavant, Anchor and Medicis

Dr Patricia Walker - Chief Medical Adviser
ex-President & Head of R&D at Brickel, CMO/CSO at Kythera, Inamed and Allergan Medical, responsible for Botox and Tazorac

These are just some key names, though there are several others in the leadership team who have extraordinary pharmaceutical experience and long-tenured careers. 

**Strategy**
Already prepared and setup production and 3rd Party Logistics, with streamlined order-to-cash systems, inventory management and customer service. 3PL is valuable for multiple reasons including reducing blocks in client/practitioner journey and also requiring no capital spend. 

Commercialisation is the next big step in BOT's transition to revenue producing pharmaceuticals company. They have begun hired a significant sales team to help push Sofdra to as many clinicians as possible. BOT has also begun engaging majorly in the Telehealth space with a client ...

Sofdra will be covered under the pharmacy benefit and does not require a code for reimbursement. HH is already recognised as a medical condition. 

Sofdra has received insurance approval and a code for the applicant. Coverage is significant for the consumer. 

A top engager in the International Hyperhidrosis Society - a society focused on promoting awareness, working to enable treatments, and increase research. 

**Financials**
Company is still cashflow negative, though is expending in relation to advancing Sofdra commercialisation and advancing regulatory approvals. 

Current cash balance of $79.3m
No debt

**Events**
BOT will begin their patient experience program in Q3 CY24, with first revenues from it being recognised in Q4 CY24. 

Recently, BOT has done a $70m equity cap raise post approval. This was to improve their balance sheet and enable enough working capital to commercialise successfully. 

**Other Notes**
Sofdra (Ecclock) has already been performing significantly well in Japan (BOT receives royalties), with company KAKEN selling 350,000 units LTM in its 3rd year on market. Though to note, the population and market in Japan is 1/3 of the US. 

**Value**
Using a reverse approach and assumptions listed below, the current share price of 0.32 (as of finalising this) highlights an expected market penetration of 0.29-0.58% for a 10y time horizon. 
Arguably, this is quite low given what is known about PAH/HH, Sofdra, the pipeline for sales, and commercialisation experience of the management team. 

Many analysts expect at least 2.5% penetration, on a base case, and 1% on a bearish case. 
Analyst base expectations for BOT's share price sits between $0.56-0.80. 
Though this is for revenues of around $89.2m USD by 2026, which may be an understatement given the recent preliminary reports (see notes below).

Assumptions
Patients seeking treatments: 3.7m
Scripts per person per year: 12
Price per script: $450-750 USD
Gross margin: 50%
P/E ratio (standardised): 10-12x

A key hint towards where sales might land can be found in the share based payments of their preliminary annual report. 
Traches 1-6 are standard, but what is interesting is Trache 7.
"Tranche 7 - Achieving US$250 million of revenue from the sale of products in a financial year."
Followed by "Management have assumed a more than likely probability of achievement of all above hurdles."

Even if this is future revenues, this is a solid sign of the revenue potential BOT has to offer. 

One other key factor to note, is that investment in Australian pharmaceuticals and the general market is quite underserviced. As it is a small market, many funds stick to the large players or stay away from smaller opportunities, which in-turn means less analysts looking into small-caps, especially pharmaceuticals. This leaves a lot of room for growth and upside in prices. 

**Key Risks**
Still pre-confirmed revenue and sales, meaning uncertainty of market share is high. This is the largest assumed risk by many investors, especially in the Australian market. A lot want to have certainty or results and confirmation it sells. Once this is seen, the share price can be expected to appreciate hugely. Currently, it is the timidity of investors which restrains it to where it sits. 

Real world usage could also be required to really prove its value - though the Japanese market has proven this to be a negligible risk.

Difficulty onboarding payers too, with out-of-pocket expenses being greater than initially expected. 

**Thesis**
The underserviced and timid Australian market is undervaluing BOT due to its inherent risk-averse investments and poor exposure to pharmaceutical financial expertise. 

The opportunity for this investment lies in the ideas that:
BOT has an FDA approved top-of-the-line product which services a condition with limited viable alternatives.

BOT has a proven management team with experience in commercialisation of pharmaceuticals, especially those in the derma space. Further, big pharma M&A successes have been realised by many of the senior leaders.

The Australian market is undervaluing the potential of BOT because a) uncertainty in product demand in the US, despite a more weary market in Japan selling hugely, b) BOT is still priced like an early stage BioTech despite entering revenue generating phase of its lifecycle and c) analysts are underpricing the value of BOT due to worries of shooting too far above market expectations and standing-out at heightened valuations (weird version of tall poppy syndrome?).

 

Catalyst

Q4 CY24 sales results,
Japanese Ecclock (Sofdra comp.) sales figures.

0 Comments
2024/11/28
21:50 UTC

1

PHAT

Voquezna launch has been amazing and the stock has dropped based on a severe overreaction. Look at the tute and insider ownership mixed with the short interest. This thing is ready to explode! GL

0 Comments
2024/11/28
18:37 UTC

13

BGM: The Underappreciated Potential Gem in the Pharmaceutical Sector

Policy Opportunities and Industry Trends Post-2024

As we approach the policy shifts following the 2024 elections, the pharmaceutical industry is poised for a new wave of growth. Upcoming healthcare reforms, an aging population, and increased government support for pharmaceutical innovation are creating unprecedented opportunities for companies like BGM ($BGM). Currently, BGM's price-to-earnings ratio is relatively low compared to the industry average, indicating that the market is significantly undervaluing its growth potential.

In recent years, BGM's stock performance has been rather subdued, partly due to the market's overall cautious stance towards pharmaceutical stocks. However, this sentiment is changing. New policies are expected to usher in more healthcare subsidies, research and development incentives, and reforms concerning drug pricing—specifically benefiting companies like BGM that have strong pharmaceutical foundations and extensive R&D experience.

Strong Fundamentals and Attractive Valuation

BGM owns Gansu Qilian Mountain Pharmaceutical, which boasts over 50 years of expertise in bioprocessing and pharmaceuticals, establishing a stable position in the global market. Nonetheless, BGM's current valuation lags significantly behind its actual business potential. While many major pharmaceutical stocks trade at price-to-earnings ratios exceeding 20, BGM stands out as a "discount treasure."

Additionally, BGM's business encompasses multiple key sectors, including biopharmaceuticals, medical devices, and health management, providing it with substantial resilience against industry risks. As new policies drive pharmaceutical innovation and the aging trend escalates, BGM is well-positioned to achieve significant revenue growth in the coming years, giving investors an opportunity to tap into this explosive potential at a relatively low valuation.

Small-Cap Surge: Capital May Gradually Return to the Pharmaceutical Sector

With policy-driven changes following the elections, capital may gradually flow back from large-cap blue-chip stocks to small-cap stocks within the pharmaceutical sector. Given that BGM is at the forefront of industry transformation, backed by robust R&D capabilities and deep industry experience, its stock could see significant appreciation in the near term.

For investors looking to capitalize on the expansion boom in the pharmaceutical industry from 2024 to 2025, BGM presents an exceptionally attractive option. Investing in BGM now not only allows one to benefit from the long-term growth potential of the pharmaceutical sector but also positions stakeholders to achieve substantial capital returns driven by policy incentives.

0 Comments
2024/11/28
09:16 UTC

0 Comments
2024/11/27
17:59 UTC

4

Novavax Financial Results And Updates On $47M Investor Settlement

I guess you all know about it, but NVAX presented its latest results with some nice news. Revenue was better than expected (smth around $85M and 15% ahead of forecasts), and even the losses per share were less than predicted. That’s a great win after the struggles they had a few years ago.

Long story short, in the old Covid times, Novavax received $1.6B from the government for the Covid vaccine development. But then, the company faced many challenges in meeting quality standards. All these production problems also led to lower vaccine quality and displeased the FDA.

After that, investors claimed that Novavax downplayed these issues and overstated its manufacturing capabilities, and hit Novavax with the lawsuit (I’m not even surprised, lol)

But, the good news is that Novavax recently agreed to pay a $47M settlement to investors to resolve this scandal. And if anyone is late, I found out that you can still file for it, they´re accepting claims even after the deadline. 

Now, they are improving its numbers (even when analysts think the coming year won’t be that great) and working on a COVID-flu shot. So we’ll see how that works out for them in the coming months.

Anyways, has anyone here had $NVAX when this happened? If so, how much were your losses?

2 Comments
2024/11/27
16:43 UTC

0

"Mainz Biomed Teams Up with Trusted Health Advisors for U.S. Launch of Innovative Colorectal Cancer Screening Test

Mainz Biomed N.V. has partnered with Trusted Health Advisors to support the U.S. launch of their next-generation colorectal cancer diagnostic test, ReconAAsense. The test, which is in its final stages of FDA premarket approval, uses innovative mRNA biomarkers to detect colorectal cancer and advanced adenomas with high accuracy. The clinical trial, set to enroll about 15,000 participants across 150 U.S. sites, aims to provide a robust, user-friendly at-home screening solution. Mainz Biomed aims to commercialize the product in the U.S. by 2026 if approved.

source: https://finance.yahoo.com/news/mainz-biomed-partners-trusted-health-130100716.html

0 Comments
2024/11/27
15:49 UTC

3

Emergent’s Stock Plunged 94% Due to the Covid Vaccine Scandal — Will It Ever Recover?

Back in Covid times, an Emergent facility mixed AstraZeneca ingredients into millions of J&J vaccine doses, exposing years of poor oversight and quality issues. The FDA halted production, leading to a 94% stock drop.

Check out the full story and how you can recover your losses now: https://www.benzinga.com/markets/24/11/42146928/emergents-vaccine-production-failure-contamination-scandal-investor-backlash-and-40m-settlement 

0 Comments
2024/11/26
20:14 UTC

3

Updates On Humanigen's $3M Investor Settlement

Hey guys, I guess there are some old HGEN investors here, and you all remember the Lenzilumab scandal they had back in COVID-19 times. I just found out that they are paying investors over this and they are accepting late claims, so you can still file to get payment even if the deadline has passed.

As you might remember, during COVID, Humanigen was accused of exaggerating how effective Lenzilumab was. The problems started when the FDA rejected it for COVID-19 use, and later, the company admitted it didn’t perform as expected in the ACTIV-5/BET-B study.

All these caused a huge $HGEN drop and investors filed a suit against them. But, the good news is that Humanigen has recently agreed to pay $3M for the investors to resolve it.

So, if someone's late, you still can file for it (they´re accepting claims even after the deadline). You can check the information and file for the payment here.

Now, after they filed for bankruptcy, a new chapter of this scandal started when one of the board members was accused of avoiding $38M in losses through insider trading. So, we’ll see how that situation ends.

Anyways, has anyone here been affected by this? How much were your losses if so?

0 Comments
2024/11/26
18:19 UTC

1

Mainz Biomed (NASDAQ: MYNZ) has partnered with Thermo Fisher Scientific (NYSE: TMO)

0 Comments
2024/11/26
15:58 UTC

2

Quantum BioPharma (Formerly FSD Pharma) Files $700M+ Lawsuit for Alleged Market Manipulation

Key Points:

  • Quantum BioPharma (NASDAQ: QNTM), formerly FSD Pharma (NASDAQ: HUGE), has filed a US$700M+ lawsuit against CIBC World Markets, RBC Dominion Securities, and others for alleged market manipulation and stock price spoofing.
  • The lawsuit claims significant financial and emotional losses for the company and shareholders.
  • Legal teams are working on a contingency basis, meaning no upfront legal costs for Quantum.

Call for Shareholders:

  • Quantum is inviting shareholders who experienced trading losses to join the case by sharing details via email or the company's "Quantum vs. Banks" webpage.
  • Shareholder participation aims to strengthen the case with broader evidence of damages.

Insights:

  • While the lawsuit seeks substantial damages, market manipulation cases face high burdens of proof and legal complexity.
  • Quantum’s rebranding from FSD Pharma adds challenges to proving historical damages.
  • The $700M claim is ambitious given Quantum’s current market cap of $10.4M.

Updates on the lawsuit will be available on Quantum BioPharma’s website.

source: https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-previously-known-as-fsd-pharma-nasdaq-huge-cse-dd1qbjnm3zal.html

2 Comments
2024/11/26
12:33 UTC

3

Aurora Launched New Product And Updates About $8M Investor Settlement

If you missed it, Aurora has just launched an upgraded line of premium medical cannabis oils in Australia. Off the back of this, the stock rose over 1% and is now up 16% year-to-date. It seems like they might finally be moving past their financial issues.

For those who aren’t familiar: back in 2019, Aurora shared glowing reports throughout the year, highlighting growing revenue and expansion plans. But by the end of the year, the truth came out—sales had dropped by 25%, and revenue fell by 33%.

This revelation sent $ACB shares tumbling, and investors filed a lawsuit against the company for the losses they faced.

The positive news? Aurora has recently agreed to an $8M settlement to resolve these claims. So, if you were an investor at the time, you can submit a claim here — they are taking claims now. 

Now, they’ve outperformed the market so far this year, with revenues of $59.47M for Q2, surpassing all estimations. 

So, what are your thoughts on Aurora’s latest results? And has anyone here invested in Aurora back then? How much were your losses if so?

0 Comments
2024/11/25
17:33 UTC

14

Altimmune ( ALT ) has a 30% short interest.

This could possibly be one of the best stocks for a short covering rally. Talke a peak.

11 Comments
2024/11/24
21:04 UTC

5

SLS Keeping people alive, tons of data coming

0 Comments
2024/11/24
09:07 UTC

11

Altimmune more than likely partnership than buy out

Buy out price and stock appreciation pretty self explanatory but how y’all think the partnership will impact price… I know milestones and some upfront payment but are we thinking just enough to run the study. So maybe a billion and then milestone ?

9 Comments
2024/11/24
03:31 UTC

1

VRNA taking over COPD

Verona recently brought their new COPD drug Ohtuvayre (ensifentrine) to market, and initial sales reports look great. Market is really warming up to Ohtuvayre in the COPD space. Just want to put this out there for anyone interested.

VRNA is one of my no-brainer long term holds along with ALT.

Cheers GLTA

1 Comment
2024/11/23
19:53 UTC

36

Alrimmune (ALT) looks like it has a promising weight loss drug that preserves lean mass

Edit: title misspelled *Altimmune

ALT just had their end of phase 2 meeting with the FDA, and they got a green light to go into phase 3 for their obesity drug pemvidutide. Pemvidutide’s lean mass preservation is best-in-class. Only 21.9% of the weight loss is from lean mass, ozempic’s semaglutide is 39.9%, which is why people end up getting Ozempic face, or look awkwardly skinny on Ozempic.

Pemvidutide is also highly effective in treating liver fibrosis because of the high ratio of glucagon to glp1. In fact, their liver fat reduction is more potent than MDGL’s resmetirom.

The market cap is extremely low still, only $600m. Carmot was a ph1 obesity drug when Roche bought them out for $2.7Bn. MDGL is currently ~$7Bn, VKTX ~5Bn, which pemV has MASH indication, and looks like it’ll work better than MDGL for the treatment of MASH.

To summarize, ALT’s Pemvidutide shows almost twice the muscle preservation of semaglutide and better MASH data than MDGL. The stock is very undervalued at $600m when comps are trading for 8x-12x that valuation.

I’m long ALT, I believe the company will be acquired soon for a good multiple of its current valuation.

27 Comments
2024/11/23
17:40 UTC

Back To Top